Nutricircle Limited is an Indian-listed R&D and science-driven nutraceutical company specializing in **Plant Protein** and **plant nutrition-based products**. The company is currently undergoing a strategic transformation under new leadership, pivoting toward high-growth segments including functional foods, dietary supplements, and sustainable agricultural supply chains. --- ### **Strategic Pivot & New Management Control** The company recently underwent a significant change in management and capital structure following an **Open Offer** by **Mr. Hitesh Mohanlal Patel**, who was designated as the **New Promoter** in **October 2023**. * **Promoter Holding:** **58.50%** (as of March 31, 2025). * **Public Holding:** **41.34%**. * **Acquisition Strength:** The net worth of the Acquirer was certified at **Rs. 45,91,50,485** (January 2023), providing a stable financial backstop for the company’s expansion. * **Inorganic Growth:** In **December 2024**, the Board approved the **100% acquisition** of **Himalaya Nutravedics India Private Limited** to consolidate management control and scale operations. --- ### **Core Product Portfolio & Market Segmentation** Nutricircle focuses on **Gluten-Free** and **High-Protein** profiles, targeting lifestyle-related health conditions such as obesity (which has seen a **20% increase** in India), diabetes, and cardiovascular diseases. | Product Category | Key Offerings & Brands | Target Market / Health Focus | | :--- | :--- | :--- | | **Next-Gen Plant Proteins** | Isolate extract protein ingredients; Peptides. | Global F&B manufacturers; launched at **Gulfood Dubai (Jan 2026)**. | | **Dietary Supplements** | **My45Nutrients™** (Launched Feb 2024). | **45 active ingredients**: 8 vitamins, 29 amino acids, 8 minerals. Focus: Immunity and stress. | | **Superfood Derivatives** | Quinoa-based flours, pastas, cereals, and beverages. | Health-conscious consumers; Diabetic/Pre-diabetic populations. | | **Functional Ingredients** | Fermented chickpea ingredients; Black rice protein isolates. | Industrial food applications; Fortified food sector. | **Geographic Focus:** Initial domestic rollout in **Mumbai, Gujarat, and Hyderabad**, with international expansion targeting **China and Southeast Asia**. --- ### **Research-Driven Ecosystem & Partnerships** The company leverages a robust network of research institutions and distribution partners to maintain a competitive edge in nutraceutical sciences. * **CSIR-CFTRI (Apr 2026):** Developing fermented chickpea ingredients for enhanced protein bioavailability. * **ICRISAT (Jun 2025):** Developing high-protein, climate-resilient chickpea cultivars. * **Barentz Distribution India (Aug 2025):** Strategic supply agreement for life science ingredients (orders confirmed within **5 business days**; **60-day** payment terms). * **Govt. of Assam (Feb 2025):** Project to isolate protein from indigenous black rice. * **Agricultural Integration:** Managing **30 acres** of contract farming in **Nagar Karnool** and a **1.8-acre** R&D unit at the **NAARM** campus to secure the Quinoa supply chain. --- ### **Diversification & Expanded Business Objects** As of **September 2023**, Nutricircle significantly broadened its constitutional objects to allow for diversification into allied and high-growth sectors: * **Agri-Tech & Food:** Grains, pulses, food additives, and protein-based additives. * **Industrial Materials:** Petrochemicals, solvents, specialty polymers, and biodegradable/eco-friendly products. * **Green Energy:** **Electric Vehicles (EV)**, batteries, and allied components. --- ### **Financial Structure & Capital Infusion** The company has aggressively raised capital to fund its transition from a trading-heavy model to an R&D and manufacturing-focused entity. * **Preferential Issue (Aug 2024):** Allotment of **97,28,211 equity shares** at **Rs. 10**, aggregating to **Rs. 9.73 Crores**. * **Convertible Instruments:** **11,00,000 warrants** issued to the Promoter at **Rs. 10** each, convertible within **18 months**. * **Debt Optimization:** Converted **Rs. 5.70 Crores** of promoter loans into equity to improve the **Debt-Equity Ratio**. * **Borrowing Capacity:** Increased limits to **Rs. 50 Crore** to support infrastructure and technology investments. * **Dividend Policy:** **No dividend** recommended for FY 2023-24 and FY 2024-25 to prioritize reinvestment. **Historical Financial Performance:** | Metric | FY 2022-23 | FY 2021-22 | FY 2020-21 | | :--- | :--- | :--- | :--- | | **Earnings Per Share (Rs.)** | **(12.69)** | **(10.95)** | **(13.21)** | | **Contingent Liabilities** | **Nil** | **Nil** | **Nil** | --- ### **Risk Profile & Mitigation** #### **1. Financial & Audit Risks** * **Qualified Audit Opinion:** Statutory auditors flagged an unrecoverable advance of **Rs. 50.00 lakhs** from **FY 2017-18** related to a failed crop cycle. Management has acknowledged this is non-recoverable. * **Liquidity & Trading:** Shares are classified under the **XT / T+1 Group** on the BSE and are considered **infrequently traded**. #### **2. Operational & Environmental Risks** * **Supply Chain Volatility:** Exposure to raw material shortages and price escalations. * **Climate Sensitivity:** Previous total crop failures (Quinoa/Chickpea) due to weather highlight the risk to the agricultural sourcing model. #### **3. Regulatory & Compliance History** * **Insider Trading:** In **February 2023**, the **CFO** was fined **Rs. 25,000** for unauthorized trades. * **Historical Non-Compliance:** The company noted past failures to trigger mandatory Open Offers in **FY 2013-14** and **FY 2018-19**. While a 2023 offer was launched, **SEBI** may still pursue actions for historical lapses. * **Foreign Exchange:** The company currently reports **nil foreign exchange risk** as it does not engage in direct imports, exports, or commodity hedging. --- ### **Investment Summary** Nutricircle Limited is a high-conviction play on the **Indian Plant Protein** market. While the company has faced historical financial losses and regulatory hurdles, the **2023-2024 recapitalization**, the entry of a **New Promoter**, and high-profile R&D partnerships with **CSIR-CFTRI** and **ICRISAT** signal a shift toward a value-added manufacturing model. Investors should monitor the successful integration of **Himalaya Nutravedics** and the commercial traction of the **My45Nutrients™** and **Black Rice Protein** initiatives.